Ultragenyx Pharmaceutical (RARE) Other Non-Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Assets data on file, last reported at $61.0 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $61.0 million, down 2.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.0 million (down 2.2% YoY), and the FY2025 annual result was $60.0 million, down 4.76% from the prior year.
• Other Non-Current Assets rose to $61.0 million in Q1 2026 per RARE's latest filing, from $60.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $63.0 million in Q4 2024 and troughed at $18.3 million in Q3 2022.
• A 5-year average of $45.6 million and a median of $53.9 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 169.42% in 2024, then declined 4.76% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $48.3 million in 2022, then grew by 19.34% to $57.7 million in 2023, then gained by 9.21% to $63.0 million in 2024, then decreased by 4.76% to $60.0 million in 2025, then gained by 1.67% to $61.0 million in 2026.
• Business Quant data shows RARE's Other Non-Current Assets at $61.0 million in Q1 2026, $60.0 million in Q4 2025, and $57.9 million in Q3 2025.